Age

65–110

Sex

ALL

Healthy volunteers

Not accepted

65+ years of age
Heart failure diagnosis and symptoms, as outlined by the 2021 European Society of Cardiology diagnostic guidelines
Residence within 50 miles of Emory University
Have undergone hemodynamic monitoring device implantation (CardioMEMS, Abbott)
Have received optimized HF therapy for 3+ months post CardioMEMS implantation

Heart failure-related hospitalization or heart failure medication changes within 1 month
Renal disease stages IV-V
Expected survival \< 12 months
Dementia or Alzheimer's disease
Limited English literacy and communication skills

Effect of DASH on HF Outcomes Heart Failure Status in Older Adults (DASH HF)